This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
In an effort to keep our shareholders and analysts informed and up to date on the progress of our promising R&D programs, we are launching
This new webinar series provides an in-depth view of Teva’s R&D strategies and progress in primary therapeutic areas in a format that is focused, detailed, and accessible.
Teva In-Focus kicks off on
Tuesday, October 8th at 8:00am Eastern Time with a focus on our
Respiratory franchise, providing insight into Teva’s commercial and R&D franchise as well as our strategy for building a leadership position in respiratory therapies.
Teva In-Focus will include a review of the global market and unmet needs, our approach to innovation and therapeutic development, and a deep dive into key projects that we believe will drive Teva’s future growth in the respiratory market.
Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific Officer, will lead the webinar and will be joined by Teva’s respiratory franchise leadership including Hans Luijendijk, Head of Global Respiratory Marketing, Global Specialty Medicine Group and Dr. Tushar Shah, Global Respiratory R&D, Teva Global R&D.
A question and answer session will follow the presentation.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.